NDAORALTABLET
Approved
Aug 2018
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
3/8 — Basic
LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE (lamivudine; nevirapine; zidovudine) by Hetero is fixed-dose combination of the hiv‑1 antiretroviral agents abacavir, dolutegravir, and lamivudine [see microbiology ()]. Approved for hiv-1 infection in adults, weighing at least 6 kg. First approved in 2018.
Drug data last refreshed 17h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
This is a fixed-dose combination oral tablet containing lamivudine, nevirapine, and zidovudine—three nucleoside/non-nucleoside reverse transcriptase inhibitors (NRTIs/NNRTIs) for HIV-1 treatment. It is indicated for HIV-1 infection in adults and pediatric patients weighing at least 6 kg. The combination works by inhibiting HIV reverse transcriptase through complementary mechanisms to suppress viral replication.
Peak
Product is at peak revenue stage; commercial teams focus on market penetration and patient retention in competitive HIV market with moderate competitive pressure (30%).
Mechanism of Action
fixed-dose combination of the HIV‑1 antiretroviral agents abacavir, dolutegravir, and lamivudine [see Microbiology ()].
Indications (2)
Worked on LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE at Hetero? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.